Organon
NEWS
The women’s health focused company acquired the drug for up to $954 million in 2021 through the acquisition of Forendo Pharma.
Organon’s workforce cuts come several months after the company’s loss of exclusivity to its second-largest product, Atozet.
A Reuters report on Friday revealed that FDA researchers have found additional molecular evidence tying blockbuster asthma therapy montelukast to adverse neuropsychiatric effects.
The sale of Dermavant clears the way for Roivant to focus on autoimmune-focused Immunovant and a slate of upcoming pivotal trials.
AbbVie’s Humira will now face competition from new biosimilars, including Boehringer Ingelheim’s Cyltezo, Celltrion’s Yuflyma, Organon and Samsung’s Hadlima, and Sandoz’s Hyrimoz.
The FDA is busy accepting drug applications, granting specialty designations and approving drugs for market. Here’s a look at this week’s FDA activity.
The global women’s health company took another step in its initiative to encourage healthcare equality for women by declaring March 8, International Women’s Day, an annual holiday.
Organon’s focus will center on reproductive health, health conditions, and issues unique to women and diseases that disproportionately impact women.
Here’s a look at who shook things up in the world of pharma and biotech this week.
JOBS
IN THE PRESS